Fate Therapeutics (FATE) pivots to autoimmune CAR T-cell therapies, with FT819 advancing toward a registrational lupus ...

Anti-drug antibody positivity often paralleled B-cell reconstitution and did not uniformly predict rituximab failure.

EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company ded ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

Children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia now have a new reason to pay attention.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Approval paves the way for CTA313 clinical study in the United States for patients with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitisBOSTON, June 09, 2026 ...

The FDA’s approval of inebilizumab has heralded a new era for patients with IgG4-related disease, while novel agents moving ...

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent ...

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Legend Biotech ...

CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.